Differential Diagnosis of Hepatic Hemangioma

Hepatic hemangiomas—benign vascular tumors composed of endothelial-lined blood-filled sinusoids—are the most common benign liver lesions encountered in clinical practice. While typically asymptomatic and discovered incidentally on imaging, their management hinges on accurate diagnosis, as several other hepatic conditions can mimic their radiologic appearance. Key differential diagnoses include hepatocellular carcinoma (HCC), metastatic liver disease, focal nodular hyperplasia (FNH), hepatic adenoma, and intrahepatic cholangiocarcinoma.

Hepatocellular carcinoma often arises in the setting of chronic liver disease or cirrhosis and may demonstrate arterial-phase hyperenhancement followed by washout on portal venous or delayed phases—a pattern that can overlap with atypical hemangiomas. Metastases, particularly from neuroendocrine tumors or melanoma, may show peripheral nodular enhancement with progressive centripetal fill-in, closely resembling the classic “fill-in” pattern of cavernous hemangiomas on contrast-enhanced MRI or CT.

Focal nodular hyperplasia typically exhibits homogeneous arterial enhancement and retains contrast on delayed imaging due to its abundant bile ductules and Kupffer cell content—features that help distinguish it from hemangiomas, which lack Kupffer cells and usually show persistent peripheral enhancement without central fill-in until later phases. Hepatic adenomas—often associated with oral contraceptive use or metabolic syndrome—may appear hypervascular but tend to lack the characteristic slow, progressive enhancement pattern of hemangiomas and carry a higher risk of hemorrhage or malignant transformation.

Intrahepatic cholangiocarcinoma, though less common, may present as a hypovascular mass with delayed, rim-like enhancement and perilesional fibrosis—findings that can be confused with large or sclerosed hemangiomas, especially on non-dynamic imaging. Accurate differentiation relies on multiphasic contrast-enhanced imaging (CT or MRI), supplemented when needed by hepatobiliary-specific MRI contrast agents (e.g., gadoxetate disodium) or biopsy in diagnostically ambiguous cases.